Brief: Cocrystal Pharma Receives Hrec Approval To Initiate Phase 1 Study To Evaluate Oral Broad-Spectrum Coronavirus 3Cl Protease Inhibitor Cdi-988
31/05/2023 13:00
May 31 (Reuters) - Cocrystal Pharma Inc COCP.O :
* COCRYSTAL PHARMA RECEIVES HREC APPROVAL TO INITIATE PHASE
1
STUDY TO EVALUATE ORAL BROAD-SPECTRUM CORONAVIRUS 3CL PROTEASE
INHIBITOR CDI-988
Source text for Eikon: ID:nGNXJ8H71
Further company coverage: COCP.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cocrystal Pharma
See all newsBrief: Cocrystal Pharma Announces Last Subject Dosed In Phase 1b Human Challenge Study Evaluating CDI-988 For Norovirus Prevention And Treatment
Cocrystal Pharma Inc reports results for the quarter ended June 30 - Earnings Summary
Cocrystal Pharma Inc expected to post a loss of 16 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Medtronic, Macy's, USA Rare Earth
U.S. STOCKS ON THE MOVE-USA Rare Earth, MiniMed, Rent the Runway